Corporate Presentation BNO (Australia: ASX); BNOEF (USA: OTCQB) nd Annual H. C. Wain inwr wrig ight t & Co. 22 nd l Global l Inves estment ment Conferen ence, ce, Sept 15, 2020 20 Central Nervous System (CNS)
Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward- looking" statements within the meaning of the United States’ Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics’ drug candidates (including BNC210, BNC105 and BNC101), its licensing agreement with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors’ drugs and drug candidates may vary from those reported when tested in different settings. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation. 2
Bionomics Investment Highlights Global, clinical stage biopharmaceutical company developing a pipeline of novel drug • candidates targeting ion channels in Central Nervous System (CNS) disorders Lead clinical candidate BNC210 in Phase 2 with Fast Track designation from FDA for Post- • Traumatic Stress Disorder (PTSD) Strategic partnership with Merck & Co., with multiple therapeutic candidates for cognitive • impairment in development for Alzheimer's Disease Emerging CNS partnering pipeline of ion channel candidates for treatment of pain and • cognitive deficits Additional value in non-core Phase 1-2 oncology assets through external funding and • partnering Experienced Management and Board of Directors • Strong international investor base • Financials: Market Capitalization (as at 7 September., 2020) of ~ A$110 M; • Cash at 30 June 2020: ~A$4.58 M; ~A$17.2 M in committed or underwritten funding 3
Bionomics’ Strategy and Value Proposition BNC210 ▪ Fund internal development for the treatment of PTSD Partnerships Finance to Phase 2b ▪ Partner/ co-development for other anxiety and stress/depression-related ▪ Leverage Merck partnership ▪ Leverage Australian R&D indications for Alzheimer’s through Tax Incentives to extend milestones & royalties cash runway ▪ Partner pre-clinical ion ▪ Establish global institutional channel programs for pain investor base and cognitive deficits ▪ Reduce internal cash burn ▪ Realize value of legacy through focus on BNC210 oncology assets through PTSD development and partnering and/or external out-sourcing model funding 4
Bionomics Stock & Financial Information BNO Share Price YTD: A$ Shar are Regis ister er Issued ed Capit ital al 626,610, 610,104 104 shares es 25 0.16 Geograp raphica cal Ownershi hip* * 20 0.13 VOLUME (M) 15 5% 5% SHARE PRICE ($) 0.10 32% 32% 10 29% 29% 0.06 5 7% 7% 0 0.03 27% 01-Jan-20 20-Jan-20 06-Feb-20 25-Feb-20 13-Mar-20 01-Apr-20 20-Apr-20 07-May-20 26-May-20 12-Jun-20 01-Jul-20 20-Jul-20 06-Aug-20 25-Aug-20 Australia UK Europe (ex UK) North America Rest of World * From the top 50 shareholdings, 62% of Registry, 18 August Volume Share Price Shareho holder struc uctu ture re 3% 3% 6% 6% Cash sh at Jun une e 30, 2020: : A$4.58MM 8MM • 23% 23% Market et capit pital aliz izati ation on of ~A$112MM 2MM (as at 7 Sept • 28% 28% t 2020 20) Signific gnificant ant Invest vestors • 5% 5% 0% 0% Apeiron n Inve vestment Group Ltd. • Biotec technolog ology Value Fund • 35% 35% Thiel Capital al • Domestic Institutions Foreign Institutions Domestic Brokers Foreign Brokers Galaxy axy Inve vestment Partners s (M Novog vograt ratz) • Employees etc. Private Stakeholders/Investors Merck & Co. • Hedge Funds Corporate Stakeholders 5
Management Team Errol rol De Souza a PhD Executive tive Chai airm rman an More tha han n 35 years experie ienc nce in biotech, big • pharma and nd academia ia Previo ious us Presid ident nt & CEO of mult ltip iple le public lic • (Biodel, Synaptic ic) & private (Neur uropore, Arche hemix ix) ) biotech h compani nies Found nder of Neurocrine ne Bioscienc nces • Previo ious us SVP Aventis ntis Pha harmaceutic icals ls • Previo ious us Head of CNS Diseases, DuPo Pont nt Merck • Mult ultip iple le public lic and nd private boards • Jack k Moschak akis BEc, Adrian Hinto ton BAEc, , FCA , DIPLa PLaw (BAB) NSW,G DipBA, , FCIS,FG FGIA Actin ting g Chief f Finan ancial al Officer Legal al Counsel & Compan pany y Secre reta tary ry Over a 43 year career at Deloit itte (Adela laide) • Over 26 years experie ience as a legal practit itio ione ner • Retir ired in 2018 as Prin incip iple le Audit it and Assur urance • Joine ined Biono nomic ics in 2015 Group up • Held senio ior Legal l / Company Secretary roles in the • Broad-based kno nowl wledge of contemporary accoun unting ng • Energy and nd Resour urces sectors and audit it issue ues in a wide rang nge of indust ustrie ies Extensiv nsive experienc nce in commercial, contractua ual • Experie ienc nce in preparing ing Due Dilig ligenc nce revie iews, ws, • and regula ulatory rela lated legal l matters investigative accoun unting ng reports and revie iew w of profit it forecasts Liz z Doolin MSc VP Clinical al Developme pment 25 year interna natio iona nal career in drug discovery, clinic inical l • and life scienc nces research Joine ined Biono nomic ics in 2008 • Extensiv nsive clinic inical l operatio ions ns and regul ulatory experie ienc nce • Oncolo logy and CNS drug develo lopment nt • Strong ng biotechn hnolo logy research and manu nufacturin ing • backgroun und 6
Bionomics’ CNS Focused Pipeline Program Pre-IND Phase 1 Phase 2a Phase 2b PTSD study, 193 pts, results released October 2018 Agitated Elderly in Hospital Setting, exploratory BNC210 study, 38 pts, results released June 2019 GAD study, 24 pts, results released α7 nAChR* Negative Allosteric Modulator September 2016 (NAM) Panic - CCK panic model in 15 healthy volunteers Nicotine-induced EEG changes in 24 healthy volunteers Merck & Co. Phase 1 Studies Ongoing Collaboration α7 nAChR* Positive Allosteric Modulator (PAM) PAIN Candidate Nav1.7/Nav1.8 Inhibitors Series COGNITION Series Lead Lead Kv3.1/3.2 Activators 7 *nAChR = nicotine acetylcholine receptor
BNC210: Next Generation Drug Candidate with Potential to Treat Anxiety, Depression, PTSD and other Stress-Related Disorders • Novel, orally-administered, first-in-class, negative allosteric modulator (NAM) of the α7 nicotinic acetylcholine receptor • Large market potential for treatment of multiple psychiatric indications • Strong safety database in man – 11 trials with exposure in ~400 subjects • Demonstrated nicotinic receptor target engagement in healthy subjects • Proof of biology in healthy subjects (anti-panic) and in Generalized Anxiety Disorder patients (anti-anxiety) Potential Competitive Advantages of BNC210* No withdrawal No memory No drug/drug Drug No sedation Fast acting syndrome impairment interactions ✓ ✓ ✓ ✓ ✓ BNC210 ✓ ✓ Valium and other x x x benzodiazepines Prozac and certain ✓ x ✓ x x other SSRIs/SNRIs *Based on data from preclinical studies, Phase 1 & 2 clinical trials. 8
Recommend
More recommend
